Literature DB >> 31758712

Perinatal compromise contributes to programming of GABAergic and glutamatergic systems leading to long-term effects on offspring behaviour.

Julia C Shaw1,2, Gabrielle K Crombie1,2, Tamas Zakar2,3, Hannah K Palliser1,2, Jonathan J Hirst1,2.   

Abstract

Extensive evidence now shows that adversity during the perinatal period is a significant risk factor for the development of neurodevelopmental disorders long after the causative event. Despite stemming from a variety of causes, perinatal compromise appears to have similar effects on the developing brain, thereby resulting in behavioural disorders of a similar nature. These behavioural disorders occur in a sex-dependent manner, with males affected more by externalising behaviours such as attention deficit hyperactivity disorder (ADHD) and females by internalising behaviours such as anxiety. Regardless of the causative event or the sex of the offspring, these disorders may begin in childhood or adolescence but extend into adulthood. A mechanism by which adverse events in the perinatal period impact later in life behaviour has been shown to be the changing epigenetic landscape. Methylation of the GAD1/GAD67 gene, which encodes the key glutamate-to-GABA-synthesising enzyme glutamate decarboxylase 1, resulting in increased levels of glutamate, is one epigenetic mechanism that may account for a tendency towards excitation in disorders such as ADHD. Exposure of the fetus or the neonate to high levels of cortisol may be the mediator between perinatal compromise and poor behavioural outcomes because evidence suggests that increased glucocorticoid exposure triggers widespread changes in the epigenetic landscape. This review summarises the current evidence and recent literature about the impact of various perinatal insults on the epigenome and the common mechanisms that may explain the similarity of behavioural outcomes occurring following diverse perinatal compromise.
© 2019 British Society for Neuroendocrinology.

Entities:  

Keywords:  GABA; allopregnanolone; behaviour; brain development; glutamate; perinatal compromise

Mesh:

Substances:

Year:  2019        PMID: 31758712     DOI: 10.1111/jne.12814

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  5 in total

1.  Maternally derived hormones, neurosteroids and the development of behaviour.

Authors:  James C Mouton; Renée A Duckworth
Journal:  Proc Biol Sci       Date:  2021-01-27       Impact factor: 5.349

2.  Thalamocortical bistable switch as a theoretical model of fibromyalgia pathogenesis inferred from a literature survey.

Authors:  Ilaria Demori; Giulia Giordano; Viviana Mucci; Serena Losacco; Lucio Marinelli; Paolo Massobrio; Franco Blanchini; Bruno Burlando
Journal:  J Comput Neurosci       Date:  2022-07-11       Impact factor: 1.453

3.  Impact of In Utero Exposure to Antiepileptic Drugs on Neonatal Brain Function.

Authors:  Anton Tokariev; Michael Breakspear; Mari Videman; Susanna Stjerna; Lianne H Scholtens; Martijn P van den Heuvel; Luca Cocchi; Sampsa Vanhatalo
Journal:  Cereb Cortex       Date:  2022-05-31       Impact factor: 4.861

4.  Examining Neurosteroid-Analogue Therapy in the Preterm Neonate For Promoting Hippocampal Neurodevelopment.

Authors:  Julia C Shaw; Rebecca M Dyson; Hannah K Palliser; Ryan P Sixtus; Heather Barnes; Carlton L Pavy; Gabrielle K Crombie; Mary J Berry; Jonathan J Hirst
Journal:  Front Physiol       Date:  2022-04-19       Impact factor: 4.755

5.  Vestibular Disability/Handicap in Fibromyalgia: A Questionnaire Study.

Authors:  Viviana Mucci; Ilaria Demori; Fabio Rapallo; Elena Molinari; Serena Losacco; Lucio Marinelli; Cherylea J Browne; Bruno Burlando
Journal:  J Clin Med       Date:  2022-07-11       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.